Hepatitis

The Pharmacy Times® Hepatitis resource center provides clinical news and articles, pertaining to the Food and Drug Administration approved therapies to treat Hepatitis A, B, and C. Additionally, pharmacists will find coverage from pertinent conferences and meetings, videos, podcasts, and other associated content.

What can we help you find?
[[thumbnail_alt_text]]
The study was done in an effort to help quickly develop pharmaceutical treatments for COVID-19 by repurposing existing drugs known to effectively treat other viral diseases, according to the study authors.
[[thumbnail_alt_text]]
Researchers have identified the role of a protein involved in the progression of hepatitis C virus (HCV) infection that has demonstrated a potential new avenue for treatment.
 
[[thumbnail_alt_text]]
Clinicians should be aware of children who are likely to have protracted illness and require hospitalization stemming from norovirus acute hepatitis, according to the results of a recent study.
[[thumbnail_alt_text]]
Successfully implementing HIV and hepatitis C testing at drug detoxification centers could help identify and link patients to care, but would require that the test results are available to nearby health care facilities.
 
[[thumbnail_alt_text]]
The coronavirus disease 2019 pandemic has presented pharmacy students with an opportunity to develop new skills that former students never had the opportunity to develop.
[[thumbnail_alt_text]]
Regular testing for hepatitis C virus has proven more effective than targeted testing.

 
[[thumbnail_alt_text]]
Which product caused hepatic failure? 
[[thumbnail_alt_text]]
Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.
[[thumbnail_alt_text]]
An overlap between substance use disorder and HCV presents an important area for screening high-risk populations.
[[thumbnail_alt_text]]
Although HCV is now curable, there are varying factors that must be considered prior to starting treatment.
[[thumbnail_alt_text]]
Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.